Control for proximity detection assays

Abstract

To provide a method for detecting a plurality of analytes in a sample.SOLUTION: Provided is a method for detecting a plurality of analytes in a sample comprising performing a multiplex proximity-based detection assay. The assay utilizes pairs of proximity probes with shared hybridization sites (i.e. pairs of proximity probes with hybridization sites which are shared between different proximity probe pairs). Also provided is a product comprising a plurality of proximity probe pairs with shared hybridization sites, which may be used in the method disclosed herein.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] Technical Field The present invention provides a method for detecting multiple analytes in a sample, comprising performing a multiplex proximity-based detection assay. The method utilizes proximity probe pairs with shared hybridization sites (i.e., proximity probe pairs with hybridization sites shared between different proximity probe pairs). Also provided are articles of manufacture containing multiple proximity probe pairs with shared hybridization sites, which may be used in the methods disclosed herein.

[0002] Background technology Modern proteomics methods require the ability to detect large numbers of different proteins (or protein complexes) in small sample volumes. To achieve this, multiplexed analyses must be performed. Common methods that may allow for multiplexed detection of proteins in a sample include the proximity extension assay (PEA) and the proximity ligation assay (PLA). PEA and PLA are described in WO01 / 61037, and PEA is further described in WO03 / 044231, WO2004 / 094456, WO2005 / 123963, WO2006 / 137932, and WO2013 / 113699.

[0003] PEA and PLA are proximity assays, which rely on the principle of "proximity probing." In these methods, an analyte is detected by binding to multiple (i.e., two or more, typically two or three) probes, and a signal is generated when the probes bind to the analyte, bringing them into proximity (hence the term "proximity probes"). Typically, at least one of the proximity probes contains a nucleic acid domain (or nucleic acid moiety) linked to the analyte-binding domain (or analyte-binding moiety) of the probe, and signal generation involves interactions between the nucleic acid domains and / or between them and additional functional moieties carried by the other probe(s). Thus, signal generation depends on the interaction between the probes (more specifically, between the nucleic acids or other functional moieties / domains carried by these probes), and thus a signal is generated only when the required probe binds to the analyte, thus improving the specificity of the detection system.

[0004] In PEA, nucleic acid moieties linked to the analyte-binding domains of a probe pair hybridize to one another when the probes are brought into proximity (i.e., bound to a target) and are extended using a nucleic acid polymerase. The nucleic acid moieties of the probes in a probe pair contain complementary "hybridization sites" that hybridize to one another. The extension product forms a reporter nucleic acid, the detection of which indicates the presence of a particular analyte (the analyte bound by the associated probe pair) in a sample of interest.

[0005] In PLA, when a probe of a probe pair binds to a target, the nucleic acid moieties attached to the analyte binding domains of the probe pair are brought into proximity, and they may ligate together, or may act together as templates for the ligation of separately added oligonucleotides that are capable of hybridizing to the nucleic acid domains upon proximity. In the PLA method, at least one "sprint" oligonucleotide is provided, which bridges adjacent probe nucleic acid moieties. The splint oligonucleotide contains a sequence complementary to a "hybridization site" on the probe nucleic acid domain. The splint oligonucleotide is then used to splint the probe nucleic acid moiety. Binding to a splint oligonucleotide allows for ligation of the two probe nucleic acid moieties. Alternatively, as described above, a second splint molecule may be added or ligated to the first splint. The ligation product is amplified and serves as a reporter nucleic acid.

[0006] Multiplexed analyte detection using PEA or PLA may be achieved by including a unique identifier (ID) sequence, such as a barcode sequence or a primer or probe binding site, in the nucleic acid portion of each probe. Reporter nucleic acid molecules corresponding to particular analytes may be identified by the ID sequence they contain.

[0007] Some "background" (i.e., false positive) signal is inevitable in proximity assays. This can occur as a result of random interactions with or between unbound proximity-probes in the reaction. Currently, the level of background signal in a proximity reaction is determined using a separate negative control. This negative control involves running the proximity assay using buffer only (i.e., no sample), so that any signal is background. By comparing the experimental assay to this negative control, true positive signals can be determined.

[0008] The present invention provides a method for performing multiplex proximity assays with improved background control. In this method, different proximity probe pairs share a hybridization site, which promotes the formation of a "background" signal among all unbound probes that share the same hybridization site. All signals from the generated reporter nucleic acids (both true and false positive) are read together. True positive signals can be distinguished from false positive signals based on whether the resulting reporter nucleic acids contain paired barcode sequences (i.e., barcode sequences that correspond to the same analyte and thus indicate a true positive signal) or unpaired barcode sequences (i.e., barcode sequences that correspond to different analytes and thus indicate a false positive signal). The level of false positive signal generated in the reaction indicates the level of background, which means that a separate negative control to determine the background level is no longer necessary, simplifying the overall assay.

[0009] The use of shared hybridization sites to determine background also reduces performance differences between different hybridization sites. Different pairs of hybridization sites interact more or less strongly than others, resulting in different levels of background from each pair of hybridization sites. The shared hybridization sites allow the level of background generated by each pair of hybridization sites to be determined individually, resulting in a more accurate assessment of the level of background. The present invention thus provides a simpler and more accurate means for controlling false-positive results in proximity assays.

[0010] Summary of the Invention To this end, the present invention provides in a first aspect a method for detecting multiple analytes in a sample comprising performing a multiplex proximity-based detection assay, said assay comprising: (i) contacting the sample with a plurality of pairs of proximal probes, each pair of proximal probes including a first proximal probe and a second proximal probe, each proximal probe comprising: (a) an analyte-binding domain specific for the analyte; (b) a nucleic acid domain; both probes in each pair comprise analyte-binding domains specific for the same analyte and are capable of simultaneously binding to said analyte, and each probe pair is specific for a different analyte from the others; the nucleic acid domain of each proximity probe comprises an ID sequence and at least a first hybridization sequence, the ID sequences of each proximity probe being different; In each proximity probe pair, the first proximity probe and the second proximity probe comprise paired hybridization sequences such that when the first proximity probe and the second proximity probe bind to the analyte, the paired hybridization sequences of the first proximity probe and the second proximity probe hybridize to each other or to a common splint oligonucleotide comprising a hybridization sequence complementary to each of the paired hybridization sequences of the first proximity probe and the second proximity probe; at least one pair of hybridization sequences is shared by at least two pairs of proximity probes; (ii) hybridizing the nucleic acid domains of the proximity probes to each other or to the splint oligonucleotide to form a continuous or discontinuous duplex comprising the hybridization sequence of a first proximity probe and the hybridization sequence of a second proximity probe, the duplex having at least one free 3' end; (iii) extension and / or ligation of the duplex to produce extension and / or ligation products comprising the ID sequence of the first proximity probe and the ID sequence of the second proximity probe; (iv) amplifying the extension product or ligation product; (v) detecting the extension products or ligation products, wherein the detection of the extension products or ligation products includes identifying the ID sequences therein, and determining the relative amounts of each extension product or ligation product; (vi) determining which analytes are present in the sample, (a) extension products and / or ligation products comprising a first ID sequence from a first proximity probe belonging to a first proximity probe pair and a second ID sequence from a second proximity probe belonging to a second proximity probe pair are considered background; (b) an extension product or ligation product comprising a first ID sequence and a second ID sequence from a proximity probe pair and present in an amount greater than the background indicates the presence of the analyte to which the proximity probe pair specifically binds in the sample.

[0011] In a second aspect, the present invention provides an article of manufacture comprising: (i) a plurality of proximity probe pairs; and optionally (ii) a plurality of splint oligonucleotides; (i) among the plurality of proximal probe pairs, each proximal probe pair includes a first proximal probe and a second proximal probe, and each proximal probe (a) a protein-binding domain specific for the protein; (b) a nucleic acid domain; both probes in each pair comprise protein-binding domains specific for the same protein and are capable of simultaneously binding to said protein, and each probe pair is specific for a different protein; the nucleic acid domain of each proximity probe comprises an ID sequence and at least a first hybridization sequence, the ID sequences of each proximity probe being different, and in each proximity probe pair, the first proximity probe and the second proximity probe comprise paired hybridization sequences; (ii) each of said plurality of splint oligonucleotides is a pair of said proximity probe pairs; and a hybridization sequence complementary to each of the hybridization sequences obtained by the hybridization sequences of each proximity probe pair are configured such that, when the first proximity probe and the second proximity probe bind to the protein, the paired hybridization sequences of the first proximity probe and the second proximity probe hybridize to each other or to a splint oligonucleotide; At least one pair of hybridization sequences is shared by at least two pairs of proximity probes.

[0012] Detailed Description As detailed above, a first aspect of the present invention provides a method for detecting multiple analytes in a sample. As used herein, the term "analyte" refers to any substance (e.g., molecule) or entity that is desired to be detected by the method of the present invention. The analyte is therefore the "target" of the assay method of the present invention, i.e., the substance to be detected or screened using the method of the present invention.

[0013] An analyte may therefore be any biological molecule or compound that one wishes to detect, for example a peptide or protein or nucleic acid molecule, or a small molecule, including organic and inorganic molecules. An analyte may also be a cell, a microorganism, including a virus, or a fragment or product thereof. It will be appreciated that an analyte may therefore be any substance or object for which a specific binding partner (e.g., affinity binding partner) can be developed. All that is required is that the analyte be capable of simultaneously binding at least two binding partners (in particular the analyte-binding domains of at least two proximity-probes).

[0014] Proximity-probe-based assays are particularly useful for detecting proteins or polypeptides. Analytes of particular interest therefore include proteinaceous molecules such as peptides, polypeptides, proteins, or prions, or any molecule containing a protein or polypeptide component, or fragments thereof. In particularly preferred embodiments of the invention, the analyte is a fully or partially proteinaceous molecule, in particular a protein. That is, the analyte preferably is or comprises a protein.

[0015] The analyte may be a single molecule or a complex containing two or more molecular subunits. The molecular subunits may or may not be covalently linked to each other, and the molecular subunits may be the same or different. Thus, such complex analytes may be not only cells or microorganisms, but also protein complexes or biomolecular complexes containing a protein and one or more other types of biomolecules. Thus, such complexes may be homomultimers or heteromultimers. Target analytes may be aggregates of molecules such as proteins, e.g., aggregates of the same protein or aggregates of different proteins. The analyte may also be a complex of a protein or peptide with a nucleic acid molecule such as DNA or RNA. Of particular interest may be the interaction of a protein with a nucleic acid, e.g., the interaction of a regulatory factor such as a transcription factor with DNA or RNA. Thus, in certain embodiments, the analyte is a protein-nucleic acid complex (e.g., a protein-DNA complex or a protein-RNA complex). In other embodiments, the analyte is a non-nucleic acid analyte, meaning an analyte that does not contain a nucleic acid molecule. Non-nucleic acid analytes include proteins and protein complexes, as described above, as well as small molecules and lipids.

[0016] The methods of the present invention are for detecting multiple analytes in a sample, which may be of the same type (e.g., the analytes may all be proteins or protein complexes) or of different types (e.g., some of the analytes may be proteins and others may be protein complexes, lipids, protein-DNA complexes, or protein-RNA complexes, or any combination of such types of analytes).

[0017] As used in this disclosure, the term "a plurality of" follows its standard definition: more than one (i.e., two or more). The terms "a plurality of" and "multiple" are interchangeable. The methods of the present invention are used to detect at least two analytes in a sample. However, it is preferred that significantly more than two analytes are detected according to the methods of the present invention. Preferably, at least 10, 20, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, or 1500 analytes are detected by the methods.

[0018] The terms "detecting" or "detected" are used to refer to: As used herein, the term "detecting" an analyte is used broadly to encompass any means of determining the presence or absence of an analyte (i.e., determining whether a target analyte is present in a sample of interest). Thus, even if the methods of the invention are performed to attempt to detect a particular analyte of interest in a sample, and the analyte is not present or detected in the sample, the step of "detecting" an analyte has occurred because the presence or absence of the analyte from the sample has been assessed. The step of "detecting" an analyte is not dependent on successful detection, i.e., that the analyte is actually detected.

[0019] Detecting an analyte may also include any form of measuring the concentration or abundance of an analyte in a sample. The absolute concentration of a target analyte may be determined, or the relative concentration of the target analyte may be determined to compare the concentration of the target analyte to the concentrations of other target analyte(s) in the sample or in another sample. Thus, "detecting" may include determining, measuring, investigating, or analyzing in some manner the presence or absence or amount of an analyte. Quantitative and qualitative determinations, measurements, or assessments are included, including semi-quantitative determinations. Such determinations, measurements, or assessments may be relative or absolute, for example, when two or more different analytes are detected in a sample. Thus, the term "quantifying" when used in the context of quantifying a target analyte in a sample can refer to absolute or relative quantification. Absolute quantification may be achieved by including one or more control analytes of known concentration(s) and / or by matching the detected level of the target analyte to known control analytes (e.g., by generating a standard curve). Alternatively, relative quantification can be achieved by comparing the detected levels or amounts of two or more different target analytes to provide relative quantification of each of the two or more different target analytes, i.e., quantification relative to one another. Similarly, the relative levels of a particular analyte in two different samples may be quantified. The manner in which quantification can be achieved in the methods of the present invention is discussed further below.

[0020] The methods of the present invention are for detecting multiple analytes in a sample. Any sample of interest may be analyzed in accordance with the present invention. This means any sample that contains or may contain an analyte of interest, and that one desires to analyze to determine whether it contains the analyte of interest and / or to determine the concentration of the analyte of interest therein.

[0021] Thus, any biological or clinical sample may be analyzed according to the present invention, for example, any cell or tissue sample from or derived from an organism, or any body fluid or preparation derived therefrom, as well as samples such as cell cultures, cell preparations, cell lysates, etc. Environmental samples, such as soil or water samples, or food samples, may also be analyzed according to the present invention. The sample may be freshly prepared or may have been pretreated in any convenient manner, for example for storage.

[0022] Representative samples, therefore, include any material that may contain biomolecules or other desired or target analytes, including, for example, food and related products, clinical samples, and environmental samples. The sample may be a biological sample, which may contain any viral or cellular material, including prokaryotic or eukaryotic cells, viruses, bacteriophage, mycoplasma, protoplasts, and organelles. Such biological material may therefore include any type of mammalian and / or non-mammalian cell, plant cell, algae, including blue-green algae, fungi, bacteria, protozoa, and the like.

[0023] The sample is preferably a clinical sample, such as whole blood, blood-derived products such as plasma, serum, buffy coat, and blood cells, urine, feces, cerebrospinal fluid or other bodily fluids (e.g., respiratory secretions, saliva, milk, etc.), tissue, biopsy tissue, etc. It is particularly preferred that the sample is a plasma or serum sample. Thus, the methods of the present invention may be used, for example, in the detection of biomarkers or to analyze samples for pathogen-derived analytes. The sample may be particularly from a human, although the methods of the present invention may equally be applied to samples from non-human animals (i.e., veterinary samples). The sample may have been pretreated or prepared for use in the methods of the present invention by any convenient or desirable technique, such as cell lysis or removal.

[0024] The methods of the present invention involve performing multiplexed proximity-based detection assays. As used herein, the term "multiplexed" refers to an assay in which multiple (i.e., at least two) different analytes are analyzed simultaneously in the same reaction mixture. However, according to the present invention, preferably, significantly more than two analytes are analyzed in a multiplex reaction. For example, a multiplex reaction may analyze at least 5, 10, 15, 20, 25, 30, 40, 50, 60, or more analytes. Certain multiplex reactions may analyze more than this number of analytes, for example, at least 70, 80, 90, 100, 110, 120, 130, 140, or 150, or more analytes.

[0025] "Proximity-based detection assay" means a method for detecting a nucleotide sequence in a sample. An assay that utilizes proximity probes to detect an analyte. Generally speaking, proximity probes interact with at least one other cognate proximity probe to detect the analyte. A proximity probe is a probe that generates a signal that can be detected to detect an analyte. Proximity probes are well known in the art. A proximity probe, as used in accordance with the present disclosure and as defined in the claims of this disclosure, is an entity comprising an analyte-binding domain specific for an analyte and a nucleic acid domain. "Specific for an analyte" means that the analyte-binding domain specifically recognizes and binds to a particular target analyte, i.e., binds to the target analyte with higher affinity than it binds to other analytes or moieties. The analyte-binding domain is preferably an antibody, particularly a monoclonal antibody. Antibody fragments or derivatives of antibodies containing the antigen-antigen binding domain are also suitable for use as the analyte-binding domain. Examples of such antibody fragments or derivatives include Fab, Fab', F(ab')2, and scFv molecules.

[0026] The Fab fragment consists of the antigen-binding domain of an antibody. An individual antibody may be considered to contain two Fab fragments, each consisting of a light chain and the N-terminal portion of a heavy chain attached to it. Thus, a Fab fragment contains the entire light chain and the V of the heavy chain to which it is attached. H Domain and Call C H 1 domain. Fab fragments are obtained by digesting antibodies with papain. may be obtained.

[0027] The F(ab')2 fragment consists of two Fab fragments of an antibody and the hinge region of the heavy domain. In other words, the F(ab')2 fragment contains two heavy chains. An ScFv molecule can be considered as two Fab fragments covalently linked together. An F(ab')2 fragment may be obtained by digesting an antibody with pepsin. The F(ab')2 fragment may be reduced to yield two Fab' fragments. These can be considered as Fab fragments containing additional sulfhydryl groups that may be useful for conjugating the fragment to other molecules. An ScFv molecule is a synthetic construct produced by fusing the variable domains of the light and heavy chains of an antibody. Typically, this fusion is performed recombinantly by engineering antibody genes to produce a fusion protein containing both the heavy and light chain variable domains.

[0028] The nucleic acid domain of a proximity probe may be a DNA domain or an RNA domain. Preferably, the diffusion domain is a DNA domain. The nucleic acid domains of each pair of proximity probes are typically designed to hybridize with each other or to one or more common oligonucleotide molecules to which the nucleic acid domains of both proximity probes in a pair may hybridize. Therefore, the nucleic acid domain must be at least partially single-stranded. In one embodiment, the nucleic acid domain of the proximity probe is entirely single-stranded. In another embodiment, the nucleic acid domain of the proximity probe is partially single-stranded and contains both single-stranded and double-stranded regions.

[0029] Proximity probes are typically provided in pairs, each pair being specific for a target analyte. As mentioned above, the target analyte may be a single entity, in particular an individual protein. In this embodiment, both probes in the proximity pair bind to the target analyte (e.g., protein), but at different epitopes. The epitopes are non-overlapping, so that it is possible for one probe of the pair to bind to its epitope. , without interfering with or blocking the binding of the other probe of the pair to its epitope. Alternatively, as discussed above, the target analyte may be a complex, e.g., a protein complex, in which one probe of the pair binds to one component of the complex and the other probe of the pair binds to the other component of the complex. The probes bind to proteins in the complex at sites that are different from the protein interaction sites (i.e., the sites through which proteins interact with each other).

[0030] As mentioned above, proximity probes are provided in pairs, each pair being specific to a target analyte. This means that in each proximity probe pair, both probes contain analyte-binding domains specific to the same analyte. Because the detection assay used is a multiplex assay, multiple different probe pairs are used in each detection assay, with each probe pair being specific to a different analyte. That is, the analyte-binding domain in each different probe pair is specific to a different target analyte. Any detection method utilizing proximity probes may be used in accordance with the present invention. As detailed above, particularly suitable proximity-based detection assays are proximity extension assays (PEA) and proximity ligation assays (PLA).

[0031] The method of the invention comprises a first step of contacting the sample with a plurality (i.e., a large number) of proximity-probe pairs, each comprising a first proximity-probe and a second proximity-probe, each comprising (a) an analyte-specific analyte-binding domain and (b) a nucleic acid domain. In each proximity-probe pair, both probes comprise the same analyte-specific analyte-binding domain, and the probe pairs are specific for distinct analytes (i.e., each probe of the pair comprises an analyte-specific analyte-binding domain).

[0032] The nucleic acid domain of each proximity probe comprises an identification (ID) sequence. Each proximity probe comprises a unique ID sequence (i.e., a unique ID sequence is present in each proximity probe). However, this does not mean that each individual probe molecule has a unique ID sequence. Rather, each probe species has a unique ID sequence. By "probe species" is meant a probe having a specific analyte binding domain; in other words, all probe molecules having the same analyte binding domain have the same unique ID sequence. Every unique probe species has a unique ID sequence. As discussed further below, the ID sequence allows for the identification of reporter nucleic acids produced in the methods of the invention.

[0033] The nucleic acid domain of each proximity probe also comprises at least one (or at least a first) hybridization sequence. The first hybridization sequence (which may be the only hybridization sequence in the proximity probe, depending on the structure of the probe used) is paired in each proximity probe pair. By "paired hybridization sequences" we mean that the two hybridization sequences in the pair are able to interact with each other, directly or indirectly, so that when the method of the invention is performed and a pair of proximity probes binds to its target analyte, the nucleic acid domains of the two probes become linked to each other, directly or indirectly.

[0034] In certain preferred embodiments, the hybridization sequences of a pair are complementary to each other and therefore hybridize to each other, in this embodiment the hybridization sequence of a first proximity probe of a pair is the reverse complement of the reverse complementary hybridization sequence of a second proximity probe of the pair. In another embodiment, the paired hybridization sequences do not hybridize directly to each other; instead, they both hybridize to separate bridging oligonucleotides, referred to herein as splint oligonucleotides. The separate oligonucleotides may be considered the third oligonucleotide in the assay method. However, more than one splint oligonucleotide may be used, and thus there may be a third or more oligonucleotides to which the paired hybridization sequences may hybridize. In other words, the paired hybridization sequences may hybridize to a common oligonucleotide. This may be a template oligonucleotide that can serve as a template for ligation and / or extension of the nucleic acid domain, or the nucleic acid domain may template the extension and / or ligation of the third or, optionally, more oligonucleotides.

[0035] In one such embodiment, the splint oligonucleotide together with the proximity probe pair may form the third component of each proximity assay set. The splint oligonucleotide has two hybridization sequences: one complementary to the hybridization sequence of the first probe in the probe pair and the other complementary to the hybridization sequence of the second probe in the probe pair. The splint oligonucleotide thus hybridizes to both of the paired hybridization sequences of the proximity probes in that proximity assay set. In particular, the splint oligonucleotide can simultaneously hybridize to both paired hybridization sequences of the proximity probes in the proximity assay set. Thus, a pair of proximity probes bind to their analyte and come into proximity, and the nucleic acid domain of the probe hybridizes to the splint oligonucleotide, thereby forming a complex comprising the two probe nucleic acid domains and the splint oligonucleotide.

[0036] In this method, at least one pair of hybridization sequences is shared by at least two pairs of proximity probes. In other words, at least two pairs of proximity probes (proximity probes that bind to different analytes) have the same hybridization sequence. Probes from a pair that share a pair of hybridization sequences can hybridize with each other or form a complex together. Hybridization is most likely to occur between the nucleic acid domains of a pair of proximity probes when both are bound to the analyte, because binding of the probes to the analyte brings the nucleic acid domains into close proximity. However, interactions can inevitably form between paired hybridization sequences of nucleic acid domains of unbound proximity probes in solution (i.e., nucleic acid domains of proximity probes that are not bound to the analyte), or when only one proximity probe is bound to its target analyte, it can interact with the other probe in solution. In particular, in solution, the nucleic acid domain of an unbound proximity probe has an equal tendency to hybridize (or form a complex) with the nucleic acid domain of any proximity probe having a paired hybridization sequence, regardless of whether the proximity probes bind to the same or different analytes. The reporter nucleic acids generated as a result of such non-specific hybridization (i.e., hybridization between unbound proximity probes in solution) form background, as described further below.

[0037] Preferably, a significant proportion of probe pairs share their hybridization sequences with at least one other proximity probe pair. In certain embodiments, at least 25%, 50%, or 75% of the proximity probe pairs share their hybridization sequences with another proximity probe pair (i.e., with at least one other proximity probe pair). In certain embodiments, all probe pairs share their hybridization sequences with at least one other proximity probe pair. However, as will be apparent from the above, in other embodiments, at least one pair of hybridization sequences is unique to a single proximity probe pair. That is, at least one pair of proximity probes does not share its hybridization sequence with any other proximity probe pair. In certain embodiments, at least 75%, 50%, or 25% of the proximity probe pairs do not share their hybridization sequences with another proximity probe pair (i.e., with any other proximity probe pair). In an embodiment of the invention, a pair of hybridization sequences is shared among all of the probe pairs that share the hybridization sequence. That is, all probe pairs that share that hybridization sequence with other probe pairs have the same pair of hybridization sequences. In this embodiment, potentially all probe pairs used in a multiplex assay may have the same pair of hybridization sequences.

[0038] However, if too many probe pairs share the same hybridization sequence pair, too many background interactions may occur, masking true positive signals. Therefore, it is preferable that each pair of hybridization sequences be shared by a more limited number of probe pairs. In certain embodiments, no more than 20, 15, 10, or 5 adjacent probe pairs share the same hybridization sequence pair. This As such, it is preferred that multiplex assays of the present invention use multiple sets of proximity probe pairs, with each proximity probe pair sharing a specific pair of hybridization sequences. In this manner, all proximity probe pairs in a particular proximity probe pair set share the same pair of hybridization sequences, but a different pair of hybridization sequences is used by each different proximity probe pair set. This allows nonspecific hybridization between all probe pairs within each probe pair set, but prevents hybridization between probe pairs in different probe pair sets. Typically, each probe pair set contains between two and five probe pairs, although larger sets may be used if desired.

[0039] The number of probe pairs used in any multiplexed assay is determined by the total number of probe pairs used in the assay, i.e., the number of different analytes detected in the assay. Inevitably, the more probe pairs used in the assay, the greater the number of probe pair sets.

[0040] The first step of the method of the present invention involves contacting the sample with multiple pairs of proximity probes as described above. The proximity probes in a pair may be premixed and added to the sample, or they may be added as individual proximity probes. That is, the sample may be contacted with each of the proximity probes in a pair separately, or the probes may be contacted simultaneously by contacting them simultaneously or in the same reaction mixture. If the proximity probes are configured such that both probes in a probe pair hybridize to a common splint oligonucleotide (rather than hybridizing to each other), the various splint oligonucleotides may be included with the proximity probe pair, or with one of the proximity probes in the pair, or may be added simultaneously or after the proximity probes. "Contacting the sample" means mixing the sample with the proximity probe pair. The proximity probe pair may be added to the sample, or vice versa. The sample may be diluted before contacting with the proximity probe pair. If dilution of the sample is necessary, this may be done using an appropriate diluent, such as a buffer. Examples of buffers suitable for use as diluents include PBS (phosphate buffered saline), TBS (Tris buffered saline), HBS (HEPES buffered saline), etc. The buffer (or other diluent) used should be carefully selected to be free of contaminant analytes. The diluent should thus be sterile, and if water is used as the diluent or as the main component of the diluent, the water used is preferably ultrapure water (e.g., Milli-Q water).

[0041] After contacting the sample with the proximity probe pair, the nucleic acid domains of the proximity probes are hybridized to each other or to a splint oligonucleotide, as appropriate. Hybridization of the nucleic acid domains to each other or to a splint oligonucleotide results in the formation of a continuous or discontinuous duplex. As used herein, a "duplex" refers to a portion of a double-stranded nucleic acid. The duplex comprises the hybridization sequence of a first proximity probe and the hybridization sequence of a second proximity probe. If the hybridization sequences hybridize to a common splint oligonucleotide rather than to each other, the duplex also comprises the common splint oligonucleotide.

[0042] In this step, hybridization of the nucleic acid domains to each other results in the formation of a continuous duplex, i.e., a single duplex containing the entire hybridization sequence of both nucleic acid domains. Hybridization of the probe nucleic acid domains to a common splint oligonucleotide results in the formation of a discontinuous duplex. The discontinuous duplex comprises a first site formed between the splint oligonucleotide and the hybridization sequence of a first probe, a second site formed between the splint oligonucleotide and the hybridization sequence of a second probe, and a gap located between the first and second sites of the duplex (i.e., between the hybridization sequences of the two probes). The discontinuous duplex may alternatively be considered as two separate duplexes (i.e., the first and second sites of the discontinuous duplex may alternatively be considered as separate first and second duplexes). Viewed in this manner, hybridization of the probe nucleic acid domains with a common splint oligonucleotide results in the formation of two linked duplexes, joined and linked by the common splint oligonucleotide.

[0043] The duplex formed by hybridizing the nucleic acid domains to one another, or the duplex formed by hybridizing the nucleic acid domains to a common splint oligonucleotide, comprises a free 3' end (or at least one free 3' end - the duplex may comprise multiple free 3' ends. In some embodiments, the duplex comprises two free 3' ends). A free 3' end is the 3' end of a nucleic acid strand of the duplex that is available for extension by a polymerase.

[0044] In this process, hybridization typically, and most frequently, occurs between the nucleic acid domains of nucleic acid probes in a proximity probe pair that bind to the target analyte. However, as noted above, background hybridization also occurs to or between the nucleic acid domains of unbound or unpaired probes in solution. Such background hybridization occurs between the nucleic acid domains of probes from a probe pair that share a common hybridization sequence.

[0045] After hybridizing the nucleic acid domains to form the duplex, the duplex is subjected to an extension and / or ligation reaction to generate an extension and / or ligation product comprising the ID sequence of the first proximity probe and the ID sequence of the second proximity probe. The nature of the reaction performed depends on whether a PLA or PEA proximity assay is performed. In PEA, only an extension reaction is performed, thus resulting in an extension product. A number of PEA variations are discussed below. In PLA, a ligation reaction is performed, although an extension reaction may also be performed. Variations of PLA are also discussed below. Preferably, the extension and / or ligation product is a linear extension product and / or linear ligation product (i.e., not a circular product).

[0046] Once the extension or ligation product is generated, it is amplified. Amplification may be performed using any well-known nucleic acid amplification technique. Preferably, amplification is performed by PCR, although any other method of nucleic acid amplification may be used, such as Loop-Mediated Isothermal Amplification (LAMP).

[0047] In a preferred embodiment, the reporter nucleic acids (i.e., extension products and / or ligation products) generated in a multiplex assay contain a common primer binding site. That is, all generated reporter nucleic acids contain the same pair of primer binding sites. This is advantageous because it allows all generated reporter nucleic acids to be amplified in a single amplification reaction using a single primer pair.

[0048] Once amplified, the reporter nucleic acid is detected. Detection of the reporter nucleic acid is achieved by detecting the ID sequence therein. The extension product or ligation product By detecting the ID sequence in the product, it is possible to determine which probes hybridized to each other to produce the product. The relative amounts of each extension or ligation product are also determined in this step. Any suitable detection method known in the art may be used.

[0049] The ID sequence may be any sequence that allows proximity probes to be distinguished or identified. It is therefore a tag sequence that allows a particular proximity probe to be detected. The ID sequence may be detected directly or may provide a binding site for a further entity that allows its detection, for example for a specific primer or detection probe. In a preferred embodiment of the present invention, the ID sequence is a barcode sequence. A barcode sequence is a specific nucleotide sequence defined to correspond to a particular analyte. If each probe has one barcode sequence, each reporter nucleic acid contains two barcode sequences, one from each of the two probes that combine to produce the product. When the two barcode sequences are detected, the two probes that combine to produce the reporter nucleic acid are identified. If the two barcode sequences are from a proximity probe pair (i.e., from a pair of probes that bind to the same target analyte), the reporter nucleic acid may indicate the presence of a target analyte in the sample or may be background. If the two barcode sequences are from unpaired proximity probes (i.e., the two barcode sequences represent different analytes), the reporter nucleic acid is considered background.

[0050] The barcode sequence is located within the nucleic acid domain of the probe. The barcode sequence is not located within the first hybridization sequence. As detailed above, each proximity probe contains a different barcode sequence, and the hybridization sequence is shared among multiple different probes. The barcode sequence is also not located within a common primer binding site. As mentioned above, each probe contains a unique barcode sequence, while all probes preferably contain a common primer binding site.

[0051] The barcode sequence can be detected in various ways. First, a specific barcode sequence may be detected by sequencing all reporter nucleic acid molecules generated during a multiplex detection assay. By sequencing all reporter nucleic acid molecules generated, all different reporter nucleic acid molecules generated may be identified by their barcode sequences. Nucleic acid sequencing is a preferred reporter nucleic acid detection / analysis method.

[0052] Other suitable methods for detecting barcodes in reporter nucleic acid molecules include PCR-based methods. For example, quantitative PCR may be performed using "TaqMan" probes. In this example, the reporter nucleic acid molecules (or at least the portion of each reporter nucleic acid molecule containing the barcode sequence) are amplified, and a probe complementary to each barcode sequence is provided, with each distinct probe conjugated to a distinct, distinguishable fluorophore. The presence or absence of each barcode is determined by the amplification of the particular barcode. The determination can be made based on whether or not the barcode sequence is present. However, combinatorial methods using probes to decode barcode sequences are known and may be used to expand the multiplexing capacity to some extent, but as mentioned above, it is clear that PCR-based methods are only suitable for simultaneously analyzing a relatively small number of different sequences. Because nucleic acid sequencing does not impose any practical limit on the number of sequences that can be distinguished in a single sequencing run and allows for a higher level of multiplexing than detection using PCR, sequencing is the preferred method for detecting reporter nucleic acid molecules.

[0053] Preferably, a form of high-throughput DNA sequencing is used to detect the barcodes in the reporter nucleic acid molecules. Sequencing by synthesis is a preferred method. The present invention relates to a method for sequencing a reporter nucleic acid. Examples of sequencing by synthesis include pyrosequencing, reversible dye terminator sequencing, and ion torrent sequencing, all of which can be used in the present method. Preferably, the reporter nucleic acid is sequenced using massively parallel DNA sequencing. Massively parallel DNA sequencing may be particularly applied to sequencing by synthesis (as described above, for example, reversible dye terminator sequencing, pyrosequencing, or ion torrent sequencing). Massively parallel DNA sequencing using the reversible dye terminator method is a preferred sequencing method. Massively parallel DNA sequencing using the reversible dye terminator method is, for example, used by Illumina.(R) NovaSeq TM This may be done using a system.

[0054] As known in the art, massively parallel DNA sequencing is a technique in which a large number (for example, thousands, or millions, or more) of DNA strands are sequenced in parallel, i.e., simultaneously. Massively parallel DNA sequencing requires that target DNA molecules are immobilized on a solid surface, for example, on the surface of a flow cell or on beads. Each immobilized DNA molecule is then sequenced individually. Generally, massively parallel DNA sequencing using reversible dye terminator sequencing utilizes a flow cell as the immobilization surface, while massively parallel DNA sequencing using pyrosequencing or ion torrent sequencing utilizes beads as the immobilization surface.

[0055] As known to those skilled in the art, immobilization of DNA molecules to a surface in massively parallel sequencing can generally be achieved by attaching one or more sequencing adapters to the ends of the molecules, allowing the DNA molecules to be attached to a target surface. Thus, the method of the present invention may include adding one or more sequencing adapters (sequencing adapters) to a reporter nucleic acid molecule, which is described in more detail below.

[0056] In another embodiment, the ID sequence is not a barcode sequence. Rather, the ID sequence may allow for identification of the probe by other means. Depending on the nature of the ID sequence, any suitable method may be used to identify the ID sequence. For example, the ID sequence may be a restriction site (i.e., a nucleotide sequence recognized by a restriction enzyme). In this embodiment, the nucleic acid domain of each proximity probe contains a distinct restriction site (such that it is recognized and cleaved by a distinct restriction enzyme). Different combinations of restriction enzymes may be applied in this manner to reporter nucleic acids generated from a multiplex assay to determine which combinations of probes interact. If the reporter nucleic acid is cleaved by both of the applied restriction enzymes of a pair, this indicates that two probes containing the respective restriction sites corresponding to the enzymes have interacted to produce the reporter nucleic acid.

[0057] In another embodiment, the ID sequence is a primer binding site. In this embodiment, the nucleic acid domain of each proximity probe contains a unique primer binding site. Different combinations of primers are used to amplify the reporter nucleic acid molecule to determine which combinations of probes interact. If an amplification reaction using a particular primer pair produces an amplification product, this indicates that the two probes containing the respective primer binding sites have interacted to produce the reporter nucleic acid. Other sequences that function in some way to identify specific probes may alternatively be used as ID sequences.

[0058] It is particularly preferred to use a barcode sequence as the ID sequence, as this allows all reporter nucleic acid molecules to be detected in a single sequencing reaction. The use of alternative forms of ID sequences, such as unique restriction sites or primer binding sites, is inefficient because each combination of restriction enzyme and primer must be tested in a separate reaction to determine which probes interact to generate reporter nucleic acids. However, there may be cases where these alternative types of ID sequences are preferable.

[0059] In this way, the reporter nucleic acid molecules (i.e., extension products or ligation products) are detected, and as detailed above, the detection involves identifying the ID sequence (preferably a barcode sequence) within each reporter nucleic acid. The detection step involves not only detecting the various reporter nucleic acid molecules produced, but also determining the relative amount of each reporter nucleic acid molecule. This may be achieved by any suitable means. High-throughput DNA sequencing, which is the preferred means of reporter nucleic acid detection as detailed above, is preferred for relative quantification of reporter nucleic acid molecules, as the number of each specific reporter nucleic acid is quantified by the sequencing reaction. As mentioned above, quantitative PCR is another suitable means by which reporter nucleic acids can be detected. Detecting reporter nucleic acid molecules by quantitative PCR allows quantification of the relative amount of each reporter nucleic acid molecule. Other suitable methods of quantifying the relative amount of each reporter nucleic acid molecule may also be used.

[0060] Once the reporter nucleic acid is detected, a step is performed to determine which analytes are present in the sample. In this step, the background level is first determined. All reporter nucleic acids generated as a result of non-specific probe interactions may be considered background interactions. The relative amount of each of these background interactions is determined to determine the background interaction level. "Non-specific probe interactions" refers to interactions between unpaired probes, i.e., between probes that bind to different analytes. Such reporter nucleic acids are extension and / or ligation products that contain a first ID sequence (e.g., barcode sequence) from a first proximity probe belonging to a first proximity probe pair and a second ID sequence (e.g., barcode sequence) from a second proximity probe belonging to a second proximity probe pair. Such reporter nucleic acids may alternatively be referred to as extension and / or ligation products that contain a first ID sequence (e.g., barcode sequence) from a proximity probe specific to a first analyte and a second ID sequence (e.g., barcode sequence) from a proximity probe specific to a second (or different) analyte. As mentioned above, non-specific interactions between unpaired proximity probes may occur between probes free in solution, or may result from sharing of their hybridization sites when only one probe is bound to its analyte.

[0061] The reporter nucleic acid generated by the specific probe interaction is then analyzed. "Specific probe interaction" refers to the interaction between probes in a probe pair, i.e., the interaction between two probes that bind to the same analyte. Such reporter nucleic acids are extension and / or ligation products that contain the first and second ID sequences (e.g., the first and second barcode sequences) from the proximity probe pair. Such reporter nucleic acids may alternatively be referred to as extension and / or ligation products that contain the first and second ID sequences (e.g., the first and second barcode sequences) from the proximity probe pair that are specific for the same analyte.

[0062] The probes in a probe pair may also interact in solution, and the reporter nucleic acid generated by the interaction of the specific probes also constitutes background (i.e., is generated as a result of background interactions). Therefore, the amount of each reporter nucleic acid generated by the interaction of the specific probes is divided by the amount of each reporter nucleic acid generated as a result of the interaction of the non-specific probes. The level of the reporter nucleic acid generated by the interaction of the specific probes is compared to the level of background interaction as determined by the amount of reporter nucleic acid generated as a result of the interaction. If the reporter nucleic acid generated by the interaction of the specific probes is present at a level higher than the level of background interaction (i.e., the level of non-specific background reporter nucleic acid), this indicates that an analyte bound by the associated probe pair is present in the sample. On the other hand, if the reporter nucleic acid generated by the interaction of the specific probes is present at a level not higher than the non-specific background reporter nucleic acid (e.g., if the reporter nucleic acid generated by the interaction of the specific probes is present at the same level as or lower than the non-specific background reporter nucleic acid), the interaction between the associated probe pair is considered to be only background. In this case, the fact that the interaction between the probes of the probe pair is only background indicates that an analyte bound by the probe pair is not present in the sample.

[0063] Alternatively, for each target molecule, background interactions may be defined only as nonspecific interactions involving probes that bind to that target molecule. That is, for each target molecule, background interactions may be defined as nonspecific interactions between a probe that recognizes the target molecule and an unpaired probe that shares a hybridization site with the probe pair that recognizes the target molecule (i.e., a probe that does not recognize the target molecule). Thus, in this case, nonspecific interactions between probes neither of which recognizes the target molecule are considered background interactions for the particular target molecule.

[0064] In certain embodiments, the background level to which the level of specific probe interaction is compared is the average level of the background interactions considered, and in particular the median level of the background interactions considered.

[0065] In certain embodiments, the first step of the method (i.e., contacting the sample with multiple pairs of proximity probes) further comprises contacting the sample with one or more background probes that do not bind to the analyte, the background probes comprising a nucleic acid domain that includes an ID sequence and a hybridization sequence shared with at least one proximity probe. A "background probe" may also be referred to herein as an "inactive probe." As noted above, the inactive probe does not bind to the analyte. Nevertheless, the inactive probe may comprise an analyte-binding domain if it is specific for an analyte, particularly an antibody, known to be absent from the sample. The inactive probe may in fact comprise a "binding domain" that corresponds to the analyte-binding domain of a functional proximity probe but does not perform analyte-binding function, i.e., the binding domain equivalent is inactive. In one embodiment, the inactive domain may be provided by bulk IgG. Alternatively, the inactive probe may comprise an inactive analyte-binding domain, i.e., a non-functional analyte-binding domain. For example, an inert probe may comprise a pseudo analyte-binding domain, such as an antibody constant region or one chain of an antibody (either the heavy or light chain only). Alternatively, an inert probe may comprise an inert domain to which a nucleic acid domain is attached but which has no function and is not associated with the analyte-binding domain of an active probe. An inert domain may be, for example, a protein, such as serum albumin (e.g., human serum albumin, bovine serum albumin), that can be added to the assay without buffering the assay reaction. In another embodiment, the inert probe is simply a nucleic acid molecule and does not comprise a non-nucleic acid domain.

[0066] Each inactive probe contains an ID sequence within its nucleic acid domain. The same type of ID sequence is used in the inactive probes as in the active (i.e., proximity) probes. For example, if the active probes use a barcode sequence as their ID sequence, the inactive probes also use a barcode sequence as their ID sequence. Each of the inactive probes contains a hybridization sequence shared with at least one proximity probe. Preferably, each of the inactive probes contains a hybridization sequence shared with multiple proximity probes. When inactive probes are used, only a single type of inactive probe may be used, i.e., all of the inactive probes have the same hybridization sequence. Preferably, however, multiple types of inactive probes are used, with each inactive probe type containing a different hybridization sequence (shared with a different proximity probe or with a different group of proximity probes). Each different type of inactive probe may have a unique ID sequence that is different from the others. Alternatively, a common inactive probe ID sequence may be used by all of the different types of inactive probes. In any case, it is clear that the ID sequence(s) used for the inactive probes are not shared with any of the proximity probes.

[0067] The hybridization site shared between an inactive probe and a proximity probe allows for background interaction between the inactive probe and the proximity probe in solution. When an inactive probe interacts with a proximity probe, a duplex is formed between the nucleic acid domains of the two probes. An extension and / or ligation reaction occurs, resulting in the formation of extension and / or ligation products from the duplex formed by the two probes. The extension and / or ligation products are amplified, processed, and detected along with all other products of the assay. The extension and / or ligation products (i.e., reporter nucleic acids) generated from the interaction between the inactive probe and the proximity probe are considered background in the determination step.

[0068] The multiplex assay used to detect an analyte in a sample is preferably PEA.In this embodiment, as described above, the nucleic acid domains of each proximity probe pair contain complementary hybridization sequences that hybridize with each other to form a duplex.The formed duplex is subjected to an extension reaction to generate an extension product.In particular, the extension product of PEA is a linear extension product.

[0069] There are several different variations of PEA, each using proximity probes with slightly different designs. The nucleic acid domain of each proximity probe is designed depending on the manner in which the probe will be used. A representative example of a proximity extension assay format is shown schematically in Figure 1, and these embodiments are described in detail below. Generally, in a proximity extension assay, when a pair of proximity probes binds to its target analyte, the nucleic acid domains of the two probes come into proximity with each other and interact (i.e., hybridize to each other directly or indirectly). The interaction between the two nucleic acid domains results in a nucleic acid duplex having at least one free 3' end (i.e., at least one of the nucleic acid domains in the duplex has an extendable 3' end). Addition or activation of a nucleic acid polymerase enzyme in the assay mixture results in extension of the at least one free 3' end. Thus, at least one of the nucleic acid domains in the duplex is extended using its paired nucleic acid domain as a template. The resulting extension product contains an ID sequence that indicates which of the two probes generated the extension product.

[0070] The nucleic acid domains of a proximity probe may be single-stranded or partially double-stranded. The nucleic acid domains may hybridize to each other, or one domain may template the extension of the other. One or both domains may be extended. When a nucleic acid domain is partially double-stranded, the single-stranded portion of the domain may be hybridized to the other domain. The strands may hybridize to each other. The single-stranded portion may thus be at the 3' end of the strand. When the nucleic acid domain is partially double-stranded, one strand may be attached to the analyte-binding domain, and the other strand may hybridize to the attached strand. In certain embodiments, the single-stranded portion of the partially double-stranded domain may be part of the strand hybridized to the attached strand. As described in more detail below, the hybridized strand of the partially double-stranded nucleic acid domain (opposite the attached strand) may be considered a "splint strand" or splint oligonucleotide.

[0071] Version 1 of Figure 1 illustrates a "traditional" proximity extension assay, in which the nucleic acid domain of each proximity probe (shown as an arrow) is attached by its 5' end to an analyte-binding domain (shown as an inverted "Y"), thereby leaving two free 3' ends. When the proximity probes bind to their respective analytes (analytes not shown), the nucleic acid domains of the probes that are complementary at their 3' ends are able to interact by hybridization, i.e., form a duplex. Addition or activation of a nucleic acid polymerase enzyme in the assay mixture extends each nucleic acid domain using the nucleic acid domain of the other proximity probe as a template, producing extension products.

[0072] Version 2 of Figure 1 illustrates an alternative proximity extension assay, in which the nucleic acid domain of a first proximity probe is attached by its 5' end to an analyte binding domain, and the nucleic acid domain of a second proximity probe is attached by its 3' end to an analyte binding domain. The nucleic acid domain of the second proximity probe therefore has a free 5' end (indicated by a blunt arrow) that cannot be extended using typical nucleic acid polymerase enzymes (which only extend 3' ends). The 3' end of the second proximity probe effectively They are "blocked", i.e., not "free", and cannot be extended because they are conjugated to, and therefore blocked by, the analyte-binding domain. In this embodiment, when the proximity probes bind to their respective analyte-binding targets, the nucleic acid domains of the probes that share a complementary region at their 3' ends are able to interact by hybridization, i.e., form a duplex. However, in contrast to version 1, only the nucleic acid domain of the first proximity probe (with its free 3' end) may be extended using the nucleic acid domain of the second proximity probe as a template to produce an extension product.

[0073] In version 3 of Figure 1, similar to version 2, the nucleic acid domain of a first proximity probe is attached to the analyte-binding domain by its 5' end, and the nucleic acid domain of a second proximity probe is attached to the analyte-binding domain by its 3' end. The nucleic acid domain of the second proximity probe therefore has a free 5' end (indicated by a blunt arrow) that cannot be extended. However, in this embodiment, the nucleic acid domain attached to the analyte-binding domain of each proximity probe does not have a complementary region and therefore cannot directly form a duplex. Instead, a third nucleic acid molecule is provided that has portions homologous to the nucleic acid domain of each proximity probe. This third nucleic acid molecule acts as a "molecular bridge" or "splint" between the nucleic acid domains. The splint oligonucleotide bridges the gap between the nucleic acid domains, allowing the diffusion domains to indirectly interact with each other, i.e., each nucleic acid domain forms a duplex with a splint oligonucleotide.

[0074] Thus, when the proximity probes bind to their respective analyte-binding targets, each of the nucleic acid domains of the probes interacts by hybridization, i.e., forms a duplex with the splint oligonucleotide. Thus, it can be considered that the third nucleic acid molecule or splint may be considered as the second strand of a partially double-stranded nucleic acid domain provided on one of the proximity probes. For example, one of the proximity probes may be provided with a partially double-stranded nucleic acid domain, and the partially double-stranded nucleic acid The domain is attached to the analyte binding domain via the 3'-end of one strand, and the other (unattached) strand has a free 3'-end. Thus, such nucleic acid domains have a terminal single-stranded region with a free 3'-end. In this embodiment, the nucleic acid domain of the first proximity probe (having the free 3'-end) may be extended using the "splint oligonucleotide" (or the single-stranded 3'-end region of the other nucleic acid domain) as a template. Alternatively or additionally, the free 3'-end (i.e., the unattached strand, or the 3'-end single-stranded region) of the splint oligonucleotide may be extended using the nucleic acid domain of the first proximity probe as a template.

[0075] As is clear from the above description, in one embodiment, the splint oligonucleotide may be provided as a separate component of the assay. In other words, the splint oligonucleotide may be added separately to the reaction mixture (i.e., added to the sample containing the analyte separately from the proximity probe). Although this may be the case, the splint oligonucleotide, even though added separately, may still be considered as a strand of a partially double-stranded nucleic acid domain, since it hybridizes to, and upon contact with, a nucleic acid molecule that is part of the proximity probe. Alternatively, the splint may be prehybridized to one of the nucleic acid domains of the proximity probe, i.e., hybridized before contacting the proximity probe with the sample. In this embodiment, the splint oligonucleotide may be considered directly as part of the nucleic acid domain of the proximity probe. That is, the nucleic acid domain is a partially double-stranded nucleic acid molecule, e.g., a proximity probe may be generated by linking a double-stranded nucleic acid molecule to an analyte binding domain (preferably where the nucleic acid domain is joined to the analyte binding domain by a single strand) and modifying the nucleic acid molecule to generate a partially double-stranded nucleic acid domain (with a single-stranded overhang that is hybridizable to the nucleic acid domain of the other proximity probe).

[0076] Therefore, the extension of the nucleic acid domain of a proximity-probe, as defined herein, also encompasses the extension of a "splint" oligonucleotide. Advantageously, when an extension product results from the extension of a splint oligonucleotide, the resulting extended nucleic acid strand binds to the proximity-probe pair only through the interaction of the two strands of the nucleic acid molecule (through hybridization of the two nucleic acid strands). Therefore, in these embodiments, the extension product may be separated from the proximity-probe pair using denaturing conditions, such as increasing the temperature or decreasing the salt concentration.

[0077] Although the splint oligonucleotide illustrated in Version 3 of Figure 1 is shown as being complementary to the entire length of the nucleic acid domain of the second proximity probe, this is merely an example, and it is sufficient for the splint to be capable of forming a duplex with (or near) the end of the nucleic acid domain of the proximity probe, i.e., to form a bridge between the nucleic acid domains of the two probes.

[0078] In other embodiments, a splint oligonucleotide may be provided as the nucleic acid domain of the third proximity probe, as described in WO2007 / 107743 (hereby incorporated by reference), which shows that this configuration can further improve the sensitivity and specificity of proximity probe assays.

[0079] Version 4 of Figure 1 is a variation of Version 1 in which the nucleic acid domain of a first proximity probe contains a sequence at its 3' end that is not perfectly complementary to the nucleic acid domain of a second proximity probe, so that when the proximity probes bind to their respective analytes, the nucleic acid domains of the probes are able to interact by hybridization, i.e., form a duplex, but the extreme 3' end of the nucleic acid domain of the first proximity probe (a nucleic acid molecule containing a free 3' hydroxyl group) is not fully complementary. The 3' end of the nucleic acid domain of the second proximity probe (the fragment) cannot hybridize to the nucleic acid domain of the second proximity probe and therefore exists as a single-stranded, unhybridized "flap". Upon addition or activation of a nucleic acid polymerase enzyme, only the nucleic acid domain of the second proximity probe can be extended using the nucleic acid domain of the first proximity probe as a template. Thus, in this embodiment, only the 3' end of the nucleic acid domain of the second proximity probe is "free" - the 3' end of the nucleic acid domain of the first proximity probe is not "free" because it is not complementary to the nucleic acid domain of the second proximity probe and therefore cannot hybridize to it and be extended.

[0080] Version 5 of Figure 1 can be considered a variation of Version 3. However, unlike Version 3, the nucleic acid domains of both proximity probes are attached by their 5' ends to their respective analyte-binding domains. In this embodiment, the 3' ends of the nucleic acid domains are not complementary to each other, so the nucleic acid domains of the proximity probes cannot interact or directly form duplexes. Instead, a third nucleic acid molecule is provided that has homology to the nucleic acid domains of each proximity probe. This third nucleic acid molecule acts as a "molecular bridge" or "splint" between the nucleic acid domains. This "splint" oligonucleotide bridges the gap between the nucleic acid domains, allowing the nucleic acid domains to indirectly interact with each other, i.e., each nucleic acid domain forms a duplex with the splint oligonucleotide. Thus, when the proximity probes bind to their respective analytes, each of the nucleic acid domains of the probes interacts by hybridization, i.e., forms a duplex with the splint oligonucleotide.

[0081] Thus, according to Version 3, the third nucleic acid molecule, or splint, can be considered as the second strand of a partially double-stranded nucleic acid domain provided on one of the proximity probes. In a preferred example, one of the proximity probes may be provided with a partially double-stranded nucleic acid domain, which is attached to the analyte-binding domain via the 5'-end of one strand, and the other (unattached) strand has a free 3'-end. Thus, such a nucleic acid domain has at least one terminal single-stranded region with a free 3'-end. In this embodiment, the nucleic acid domain of the second proximity probe (having a free 3'-end) may be extended using a "splint oligonucleotide" as a template. Alternatively or additionally, the free 3'-end of the splint oligonucleotide (i.e., the unattached strand, or the 3'-terminal single-stranded region of the first proximity probe) may be extended using the nucleic acid domain of the second proximity probe as a template.

[0082] As described above in relation to Version 3, the splint oligonucleotide may be provided as a separate component of the assay. Alternatively, the splint oligonucleotide may be added separately or considered as a strand of a partially double-stranded nucleic acid domain, since it hybridizes to, and upon contact with, a nucleic acid molecule that is part of a proximity probe. Alternatively, the splint may be pre-hybridized to one of the nucleic acid domains of the proximity probe, i.e., hybridized before contacting the proximity probe with the sample. In this embodiment, the splint oligonucleotide may be considered directly as part of the nucleic acid domain of the proximity probe. That is, the nucleic acid domain is a partially double-stranded nucleic acid molecule; for example, a proximity probe may be generated by linking a double-stranded nucleic acid molecule to an analyte-binding domain (preferably, the nucleic acid domain is joined to the analyte-binding domain by a single strand) and modifying the nucleic acid molecule to generate a partially double-stranded nucleic acid domain (with a single-stranded overhang that is hybridizable to the nucleic acid domain of the other proximity probe).

[0083] Therefore, the extension of the nucleic acid domain of a proximity probe as defined herein is referred to as a "sprint." This also includes extension of the oligonucleotide. Advantageously, when an extension product is generated from the extension of the splint oligonucleotide, the resulting extended nucleic acid strand binds to the proximity-probe pair only through the interaction of the two strands of the nucleic acid molecule (through hybridization of the two nucleic acid strands). Therefore, in these embodiments, the extension product may be separated from the proximity-probe pair using denaturing conditions, such as increasing the temperature or decreasing the salt concentration.

[0084] Although the splint oligonucleotide illustrated in Version 5 of Figure 1 is shown as being complementary to the entire length of the nucleic acid domain of the first proximity probe, this is merely an example, and it is sufficient for the splint to be capable of forming a duplex with (or near) the end of the nucleic acid domain of the proximity probe, i.e., to form a bridge between the nucleic acid domains of the proximity probe.

[0085] In other embodiments, a splint oligonucleotide may be provided as the nucleic acid domain of the third proximity probe, as described in WO2007 / 107743 (hereby incorporated by reference), which shows that this configuration can further improve the sensitivity and specificity of proximity probe assays.

[0086] Version 6 of Figure 1 is the most preferred embodiment of the present invention. As shown, both probes of the pair are attached to a partially single-stranded nucleic acid molecule. In each probe, a short nucleic acid strand is attached to an analyte-binding domain via its 5' end. The short nucleic acid strands attached to the analyte-binding domain do not hybridize to each other, but each hybridize to a long nucleic acid strand. The long nucleic acid strands have single-stranded overhangs at their 3' ends (i.e., the 3' end of the long nucleic acid strand extends beyond the 5' end of the short strand attached to the analyte-binding domain). The overhangs of the two long nucleic acid strands hybridize to each other to form a duplex. The long nucleic acid strands hybridize to each other, and are referred to herein as "hybridization oligonucleotides." As shown, if the 3' ends of two long nucleic acid molecules hybridize entirely to each other, the duplex will have two free 3' ends, while the 3' ends of the long nucleic acid molecules may be designed as in version 4, with the extreme 3' end of one of the long nucleic acid molecules. is not complementary to the other and forms a flap, meaning that the duplex contains only one free 3' end.

[0087] Thus, when the methods of the invention are performed using PEA, in some embodiments, at least one nucleic acid domain in each proximity-probe pair will be partially double-stranded, either in one configuration (such as versions 3 and 5) or preferably in both configurations (such as version 6) within each proximity-probe pair.

[0088] As detailed for version 6, preferably the partially double-stranded nucleic acid domain comprises: (i) a first oligonucleotide conjugated to an analyte binding domain; (ii) a hybridization oligonucleotide comprising the first hybridization sequence, the ID sequence, and a second hybridization sequence, wherein the first hybridization sequence is located at the 3' end of the hybridization oligonucleotide; The double-stranded portion of the nucleic acid domain comprises a duplex between the second hybridization sequence of the hybridization oligonucleotide and the first oligonucleotide, and the single-stranded portion of the nucleic acid domain comprises the first hybridization sequence of the hybridization oligonucleotide.

[0089] In certain embodiments, the hybridization oligonucleotide comprises, from the 5' end to the 3' end, the second hybridization sequence, the ID sequence (preferably a barcode sequence), and the first hybridization sequence, and the ID sequence (preferably a barcode sequence) is located in the single-stranded portion of the nucleic acid domain.

[0090] All proximity probes may contain the same first oligonucleotide and the same second hybridization sequence (in the hybridization oligonucleotide). In other words, all proximity probes may contain a universal first oligonucleotide. The primer and second hybridization sequence may be shared, which may result in a more straightforward manufacturing process for the probe.

[0091] As described above, the first oligonucleotide and the second hybridization sequence are complementary to each other, allowing the two sequences to hybridize with each other. In certain embodiments, the second hybridization site is complementary to the entire first oligonucleotide, so that the duplex formed therebetween includes the entire first oligonucleotide. However, this is not required; the second hybridization site may be complementary to only a portion of the first oligonucleotide, so that the duplex formed therebetween includes only a portion of the first oligonucleotide. As described above, the first hybridization sequence is located at the 3' end of the hybridization oligonucleotide, so that when two probes complementary to the first hybridization sequence are adjacent, the 3' ends of the hybridization oligonucleotides hybridize to each other. "Located at the 3' end" may mean that the first hybridization sequence extends to the 3' end of each hybridization oligonucleotide, i.e., the first hybridization sequence may include the 3' nucleic acid of each hybridization oligonucleotide. However, this is not required, and the first hybridization sequence may extend only onto the 3' end of one hybridization oligonucleotide in each probe pair. The nucleic acid domain used in version 6 of the PEA may thus be designed similarly to version 4, so that one of the hybridization oligonucleotides of each probe pair contains a sequence at its 3' end that is not fully complementary to the hybridization oligonucleotide of the other proximity probe, thus forming a single-stranded, unhybridized "flap".

[0092] Thus, after the two nucleic acid domains are hybridized to each other, at least one hybridization oligonucleotide is extended to generate an extension product (i.e., one or both hybridization oligonucleotides are extended to generate an extension product). If the first hybridization sequence extends to the 3'-end of both hybridization oligonucleotides in each probe pair, both hybridization oligonucleotides may be extended to generate an extension product. On the other hand, if one of the hybridization oligonucleotides has an unhybridized flap at its 3'-end (as described in detail above), only one of the hybridization oligonucleotides is extended to generate an extension product (i.e., a hybridization oligonucleotide without a flap).

[0093] When the multiplex assay performed is a PEA, it is preferred that the extension reaction be performed in conjunction with a PCR amplification, in other words, a single reaction including a PCR amplification is performed to achieve both the extension of the proximity-probe nucleic acid domains to generate reporter nucleic acid molecules and the amplification of the generated reporter nucleic acid molecules. In this embodiment, rather than first performing a denaturation step (as is normally done even in PCR), the reaction first performs an extension step, whereby reporter nucleic acid molecules are amplified. A reporter nucleic acid molecule is generated. Standard PCR is then performed to amplify the reporter nucleic acid molecule and initiate denaturation of the reporter molecule. As detailed above, the PCR is preferably performed using common primers that bind to a common sequence at the ends of the reporter nucleic acid molecule. As detailed below, one or both of the primers may contain a sequencing adapter. In other words, the extension and amplification steps of the method of the present invention may be performed in a single reaction.

[0094] In another embodiment, the multiplex assay used to detect analytes in a sample is preferably PLA. The PLA used may be "standard" PLA, which refers to a PLA that uses a single splint oligonucleotide to join the nucleic acid domains of two proximity probes. In standard PLA, the nucleic acid domain of each proximity probe pair contains a paired hybridization sequence that hybridizes to a splint oligonucleotide to form a duplex. The nucleic acid domains of the proximity probe pair are joined to their respective probes such that in each pair, one proximity probe has a nucleic acid domain with a free 3' end and the other proximity probe has a nucleic acid domain with a 5' end, so that the free ends of the nucleic acid domains of the two probes can be ligated together. The splint oligonucleotide contains an extension blocker at its 3' end. ) and therefore cannot be extended. After forming the duplex, the nucleic acid domains of the two proximity probes are ligated to each other, either directly or indirectly, to produce a ligation product comprising the ID sequence of the first proximity probe and the ID sequence of the second proximity probe.

[0095] When the multiplex assay is a PLA, the nucleic acid domains of the two proximity probe pairs preferably hybridize to the splint oligonucleotides such that there is no gap in the duplex between them. In other words, the 3' end of one nucleic acid domain may hybridize to the splint nucleotide immediately adjacent to the splint nucleotide to which the 5' end of the other nucleic acid domain hybridizes. This allows for direct ligation of the two nucleic acid domains to one another. Alternatively, the nucleic acid domains of a proximity probe pair may hybridize to a splint oligonucleotide such that a gap is formed between the 3' end of one nucleic acid domain and the 5' end of the other nucleic acid domain. In this embodiment, the duplex formed between the splint oligonucleotide and the two probe nucleic acid domains contains one single-stranded nucleic acid from the splint oligonucleotide, which separates the two portions of the duplex. The single-stranded gap may be any nucleotide length. In this embodiment, a gap-filling extension is used to fill the gap between the ends of the two probe nucleic acid domains. A reaction is performed (i.e., the probe nucleic acid domain at the free 3' end is extended to fill the gap). After filling the gap, the nucleic acid domains of the two splint oligonucleotides are ligated to each other using a ligase enzyme. Ligating the nucleic acid domains to each other after filling the gap is referred to herein as "indirect ligating" the nucleic acid domains to each other.

[0096] The gap-filling extension reaction is carried out using a polymerase enzyme that lacks strand displacement, so that extension stops when the gap is filled and the hybridized nucleic acid domain downstream of the free 3' end is not displaced. An example of a non-displacing polymerase is T4 DNA polymerase. Other such polymerases are known in the art.

[0097] After ligation, the ligation product is amplified (e.g., by PCR) and detected as described above. In these PLA embodiments, a linear ligation product (or extension-ligation product) is generated. Ligation product, or Preferably, the extension and ligation products produced by the methods of the present invention are linear.

[0098] Alternatively, the PLA used may be rolling circle amplification PLA (PLA-RCA). This PLA format uses two splint oligonucleotides that ligate to each other to generate a ligation product. PLA-RCA is described, for example, in Soderberg et al., Nature Methods 3(12): 995-1000 (2006). In this embodiment, each proximity probe comprises a nucleic acid domain containing two hybridization sequences. The first hybridization sequence is complementary to a hybridization sequence on a first splint oligonucleotide, and the second hybridization sequence is complementary to a hybridization sequence on a second splint oligonucleotide. The first hybridization sequences are paired as described above, and the same pair of first hybridization sequences is shared by multiple proximity probe pairs. As detailed above, these hybridize to a specific first splint oligonucleotide. The second hybridization sequences may also be paired, but more preferably, they are universal sites shared by all proximity probe nucleic acid domains in a multiplex assay, so that only one second splint oligonucleotide is required for all proximity probe pairs.

[0099] In PLA-RCA, the ID sequence (preferably a barcode sequence) of the probe nucleic acid domain is located between the first and second hybridization sites. When two splint oligonucleotides are attached to the probe nucleic acid domain, a gap-filling extension reaction occurs, as described above. The two splint oligonucleotides are then ligated together to form a circular molecule, which is amplified by rolling circle amplification and detected.

[0100] As mentioned above, it is preferable to detect the reporter nucleic acid by massively parallel DNA sequencing, which generally requires sequencing the addition of sequencing adapters to DNA molecules. As detailed above, the sequencing adapters function to immobilize the DNA molecules on a surface.

[0101] The method of the invention may thus comprise adding one or more adaptors for sequencing (sequencing adaptors) to the reporter nucleic acid.

[0102] Typically, a sequencing adapter is a nucleic acid molecule (e.g., a DNA molecule). In this example, a short oligonucleotide complementary to the adapter sequence is attached to an immobilization surface (e.g., the surface of a bead or flow cell), allowing the target DNA molecule to anneal to the surface via the adapter sequence. Alternatively, some other pair of binding partners can be used to attach the target DNA molecule to the immobilization surface, such as biotin and avidin / streptavidin. In this case, biotin can be used as the sequencing adapter, and avidin or streptavidin can be attached to the immobilization surface to bind the biotin sequencing adapter, or vice versa.

[0103] Sequencing adapters may thus be short oligonucleotides (preferably DNA) and may generally be 10-30 nucleotides in length (e.g., 15-25 nucleotides, or 20-25 nucleotides in length). As detailed above, the purpose of the sequencing adapter is to allow annealing of the target DNA molecule to the immobilization surface, and therefore the nucleotide sequence of the nucleic acid adapter is determined by the sequence of the binding partner attached to the immobilization surface. Alternatively, the nucleic acid sequencing adapter may be There are no particular restrictions on the nucleotide sequence.

[0104] Sequencing adapters may be added to the reporter nucleic acids of the present invention during PCR amplification. In the case of nucleic acid sequencing adapters, this can be done by including sequencing adapter nucleotides in one or both primers. Alternatively, if the sequencing adapter is a non-nucleic acid sequencing adapter (e.g., a protein / peptide or small molecule), the adapter may be attached to one or both PCR primers. Alternatively, the sequencing adapter may be attached to the reporter nucleic acid molecule by directly ligating or attaching the sequencing adapter to the reporter nucleic acid molecule. Preferably, the one or more sequencing adapters used in the present method are nucleic acid sequencing adapters.

[0105] One or more nucleic acid sequencing adapters may thus be added to the reporter nucleic acid in one or more ligation and / or amplification steps. Thus, for example, if sequencing adapters are added to the reporter nucleic acid molecule (one at each end), they may be added in one step (e.g., by PCR amplification using a pair of primers, both of which contain a sequencing adapter) or in two steps. The two steps may be performed using the same method or different methods. For example, a first sequencing adapter may be added to the reporter nucleic acid molecule by ligation, and a second sequencing adapter may be added by PCR amplification, or vice versa. Alternatively, a first amplification reaction may be performed to add a first sequencing adapter to the reporter nucleic acid molecule, followed by a second amplification reaction to add a second sequencing adapter to the reporter nucleic acid molecule.

[0106] As mentioned above, one or more sequencing adapters may be added to a reporter nucleic acid molecule. This means one or two sequencing adapters - since sequencing adapters are added to the ends of a DNA molecule, the maximum number of sequencing adapters that can be added to a single DNA molecule (e.g., reporter nucleic acid) is two. Thus, a single sequencing adapter may be added to one end of a reporter nucleic acid molecule, or two sequencing adapters may be added, one to each end of a reporter nucleic acid molecule. In certain embodiments, Illumina p5 adapters and Illumina p6 adapters are used. A P7 adapter is used, i.e., a P5 adapter is used for the reporter nucleic acid molecule. A P5 adaptor is added to one end of the fragment and a P7 adaptor is added to the other end. The sequence of the P5 adaptor is shown in SEQ ID NO: 1 (AAT GAT ACG GCG ACC ACC GA), and the sequence of the P7 adaptor is shown in SEQ ID NO: 2 (CAA GCA GAA GAC GGC ATA CGA GAT).

[0107] PCR amplification can be combined with the addition of one or more sequencing adaptors to reporter nucleic acid molecules. This can be achieved by amplifying reporter nucleic acid molecules using a primer pair that includes at least one sequencing adaptor. In this example, at least one primer in the primer pair includes a sequencing adaptor upstream of the sequence that binds to the reporter nucleic acid molecule. The sequencing adaptor is generally located at the 5' end of the primer that contains it.

[0108] In certain embodiments, the amplification step is carried out using a primer pair that includes one primer that includes a sequencing adapter, such that a single sequencing adapter is added to one end of the reporter nucleic acid molecule.

[0109] In other embodiments, the amplification step is performed using a primer pair in which both primers contain a sequencing adapter, thereby allowing amplification of the sequencing adapter in a single amplification step. A primer is added to each end of the reporter nucleic acid molecule.

[0110] In other embodiments, two separate amplification reactions are performed to add a sequencing adapter to each end of the reporter nucleic acid molecule, with each amplification step adding a different sequencing adapter to a different end of the molecule.

[0111] In other embodiments, an initial amplification step is performed using primers that do not contain sequencing adapters, and the amplified reporter nucleic acid molecules are then subjected to one or more further amplification reactions to add sequencing adapters to each end of the molecules, as described above.

[0112] Preferably, the reporter nucleic acid (i.e., extension product and / or ligation product) is amplified in two PCR steps. In a first PCR reaction, a first sequencing adapter is added to one end of the extension product or ligation product. The product of the first PCR reaction is then amplified in a second PCR reaction, in which a second sequencing adapter is added to the other end of the reporter nucleic acid. In a specific embodiment, as described in WO2012 / 104261, the first PCR reaction is performed with a nucleic acid polymerase that also has 3' to 5' exonuclease activity, and the second PCR reaction is performed with a nucleic acid polymerase that is deficient in 3' to 5' exonuclease activity. Suitable examples of nucleic acid polymerases with 3' to 5' exonuclease activity include T4 DNA polymerase, T7 DNA polymerase, Phi 29, Φ29 DNA polymerase, DNA polymerase I, Klenow fragment of DNA polymerase I, Pyrococcus furiosus iosus (Pfu) DNA polymerase, and Pyrococcus woesei (Pwo) DNA polymerase. Suitable examples of nucleic acid polymerases deficient in nuclease activity include the α subunit of DNA polymerase III, the Klenow exo(−) fragment of DNA polymerase I, Taq polymerase, Pfu(exo−) DNA polymerase, and Pwo(exo−) DNA polymerase.

[0113] In other embodiments, the same polymerase may be used for both PCR steps, for example, Pwo polymerase or Pfu polymerase.

[0114] The methods of the present invention may be used to simultaneously analyze multiple samples. In this case, a separate multiplex assay is performed as described above for each sample. As extension and / or ligation products are generated, a sample index sequence is added. The sample index is a nucleotide sequence that identifies the sample from which the extension and / or ligation products originated. For each extension and / or ligation product derived from a different sample, a different nucleotide sequence is used as the sample index sequence. Conversely, all extension and / or ligation products from a particular sample are labeled with the same sample index sequence.

[0115] Once all products are labeled with a sample index, the products of multiple samples may be pooled together and analyzed. If the reporter nucleic acid is sequenced, the sample index indicates which sample each individual reporter nucleic acid molecule originated from. A nucleotide sequence may be used as the sample index. The sample index sequence can be any length, but is preferably relatively short, e.g., 3-12 nucleotides, 4-10 nucleotides, or 4-8 nucleotides in length.

[0116] The sample index sequences are linked to the extension products and / or ligated sequences in any suitable manner. The sample index may be added to the reaction product, for example, during an amplification reaction (e.g., PCR) or a ligation reaction. In particular, if the reporter nucleic acid molecule is to be analyzed by massively parallel DNA sequencing, which requires sequencing adapters at both ends, the sample index sequence should not be added so that it is ultimately located at the end of the reporter nucleic acid molecule.

[0117] In a preferred embodiment, a sample index sequence is added to the extension product and / or ligation product during PCR amplification. As described above, a sequencing adapter may also be added to the extension product and / or ligation product during PCR amplification. In certain embodiments, a dedicated amplification step may be performed solely to add a sample index to a reporter nucleic acid molecule. In other embodiments, a sample index may be added simultaneously with one or more sequencing adapters during PCR amplification. For example, if a single PCR amplification is performed to add sequencing adapters to both ends of a reporter nucleic acid molecule, the sample index may be added simultaneously. Alternatively, if two sequential PCR amplification steps add sequencing adapters to each end of a reporter nucleic acid molecule, the sample index may be added in either PCR amplification step. The sample index may be added in the first PCR amplification step, in which case the sample index may be added to the reporter nucleic acid molecule at the same end (inward from the sequencing adapter) as the end to which the sequencing adapter is added, or at the opposite end. Alternatively, a sample index may be added in a second PCR amplification step, in which case the sample index should be added to the reporter nucleic acid molecule at the same end as the sequencing adapter is added to the reporter nucleic acid molecule (inner of the sequencing adapter). Alternatively, a ligation step may be performed prior to amplification to add a sample index to the end of each reporter nucleic acid molecule.

[0118] A second aspect of the invention is an article of manufacture that may be used to carry out the method of the first aspect of the invention. In particular, as described above, the article of manufacture comprises: (i) a plurality of proximity probe pairs; and optionally (ii) a plurality of splint oligonucleotides; (i) among the plurality of proximal probe pairs, each proximal probe pair includes a first proximal probe and a second proximal probe, and each proximal probe (a) a protein-binding domain specific for the protein; (b) a nucleic acid domain; both probes in each pair comprise protein-binding domains specific for the same protein and are capable of simultaneously binding to said protein, and each probe pair is specific for a different protein; the nucleic acid domain of each proximity probe comprises an ID sequence and at least a first hybridization sequence, the ID sequences of each proximity probe being different, and in each proximity probe pair, the first proximity probe and the second proximity probe comprise paired hybridization sequences; (ii) each of said plurality of splint oligonucleotides comprises a hybridization sequence complementary to each of said paired hybridization sequences of a proximity probe pair; the hybridization sequences of each proximity probe pair are configured such that, when the first proximity probe and the second proximity probe bind to the protein, the paired hybridization sequences of the first proximity probe and the second proximity probe hybridize to each other or to a splint oligonucleotide; At least one pair of hybridization sequences is shared by at least two pairs of proximity probes.

[0119] The various components of this embodiment are the same as the equivalent components of the first embodiment (e.g., proximity probes, ID sequences, splint oligonucleotides, hybridization sequences, etc.). Notably, in this embodiment of the invention, both probes in each probe pair contain protein-binding domains specific for the same protein. In other words, in each probe pair of the product, both probes bind to the same protein. As detailed above, the two probes in each probe pair bind to the target protein at different epitopes, so they do not interfere with each other's binding to the target. Probes of the invention may be designed for use with any type or variant of PEA or PLA, as described above.

[0120] In one embodiment, as described above, the article of manufacture of the invention further comprises one or more background probes (or inactive probes) that do not bind to the analyte. As in the methods of the present invention, it is preferred that a significant proportion of the probe pairs share their hybridization sequences with at least one other proximity probe pair. In certain embodiments, as in the present methods, at least 25%, 50%, or 75% of the proximity probe pairs share their hybridization sequences with another proximity probe pair (i.e., with at least one other proximity probe pair). In certain embodiments, all probe pairs share their hybridization sequences with at least one other proximity probe pair. However, as will be apparent from the above, in other embodiments, at least one pair of hybridization sequences is unique to a single proximity probe pair. That is, at least one pair of proximity probes does not share its hybridization sequence with any other proximity probe pair. In certain embodiments, at least 75%, 50%, or 25% of the proximity probe pairs do not share their hybridization sequences with another proximity probe pair (i.e., with any other proximity probe pair). As with the method, in some embodiments, no more than 20, 15, 10, or 5 proximity probe pairs in the product share the same hybridization sequence pair.

[0121] The products of the invention may be provided as a single composition containing all of the proximity probes (and, optionally, splint oligonucleotides and / or inert probes). Alternatively, all components of the product may be provided in separate containers. For example, the proximity probe pair, splint oligonucleotide, and inert probe may all be provided in separate containers. If desired, each probe pair or each proximity probe may be provided in a separate container, as may each different splint oligonucleotide and each different inert probe.

[0122] The article of manufacture may also further comprise additional components for use in the methods of the invention. For example, the article of manufacture may include one or more nucleic acid polymerase enzymes for use in the extension and / or amplification steps, and / or a ligase enzyme if a ligation step is required. The article of manufacture may include primers for use in amplification. As detailed above, the primers used in the amplification step(s) may include sequencing adapters for nucleic acid sequencing and / or sample index sequences. The article of manufacture may also include nucleotides (e.g., dATP, dCTP, dGTP, and dTTP) for use in the extension / amplification reaction. The article of manufacture may also include a solid substrate, such as a flow cell or beads, on which a reporter nucleic acid molecule can be immobilized for sequencing.

[0123] The invention will be further understood by reference to the following non-limiting examples and drawings. [Brief explanation of the drawings]

[0124] [Figure 1] Figure 1 shows a schematic diagram of the six different versions of the proximity extension assay detailed above. The inverted "Y" shape represents an antibody as an example of a proximity probe analyte binding domain. [Figure 2] Figure 2 shows the expression levels of four analytes in six different samples as determined by multiplex PEA using either a conventional negative control or a shared hybridization site negative control. [Figure 3] Figure 3 shows the expression levels of five analytes in six different samples (the same samples used in Figure 2) as determined by multiplex PEA using either a conventional negative control or a shared hybridization site negative control.

[0125] Example Plasma samples were obtained from six donors: three healthy subjects, one subject diagnosed with breast cancer, one subject diagnosed with rheumatoid arthritis (RA), and one subject diagnosed with inflammatory bowel disease (IBD). Multiplex PEA was performed to detect the following nine proteins in the samples (using probes containing antibodies conjugated to nucleic acid domains with the structures described in version 6 above): NPDC1 (UniProtQ9NQX5); AHCY (UniProtP23526); TM (UniProtP07204); ANGPTL1 (UniProtO95841); LOX-1 (UniProtP78380); SEMA3F (UniProtQ13275); CDH2 (UniProtP19022); CANT1 (UniProtQ8WVQ1); and CA13 (UniProtQ8N1Q1). The probes targeting NPDC1, AHCY, TM, and ANGPTL1 all shared a pair of hybridization sites. The probes targeting LOX-1, SEMA3F, CDH2, CANT1, and CA13 all shared a different pair of hybridization sites. Each probe had a unique barcode sequence. A negative control containing phosphate buffered saline containing 1% bovine serum albumin without sample was also used.

[0126] PEA was performed as described above. During amplification of the extension products, P5 and P7 sequencing adapters were added to each end of the products, along with a unique sample index for the reporter nucleic acid from each distinct sample, and all extension products were subjected to reversible dye terminator sequencing using the Illumina NovaSeq platform. All extension products were sequenced by massively parallel DNA sequencing using the .beta.-sequencing technology.

[0127] The background from the standard negative control for a target was determined from the interactions of the paired barcodes of the probes for the target. The background from shared hybridization sites for a target was determined for each sample from the average of mismatched interactions (determined by mismatched barcodes) between each probe of the target probe pair and other probes in the group (probes that share the hybridization site of the target probe). In other words, for each target, the background from shared hybridization sites was defined as the nonspecific interactions between each probe of the target and other probes with shared hybridization sites. Nonspecific interactions between probes neither of which binds to the target were included in the background calculation.

[0128] The following results were obtained for the two groups of target analytes. [Table 1] [Table 2] The results of the logarithm analysis are shown in the graph in FIG.

[0129] [Table 3] [Table 4] The results of the logarithm analysis are shown in the graph in FIG.

[0130] For both groups of analytes, the actual values ​​of signal above background were Although there may be differences between the two types of controls (negative control and shared hybridization site control), the values ​​will be shifted approximately equally for each analyte in each sample (i.e., there will be a parallel shift). This allows for a high R for the results obtained for each analyte. 2 These are expressed by the values ​​of The results show a very high correlation between the degree of signal above background determined by each method. Because the relative signal levels of the analytes are preserved between samples, the results demonstrate that using a shared hybridization site is a valid alternative to a standard negative control. Results obtained from determining background from a shared hybridization site demonstrate discrimination between samples, similar to that achieved using a standard negative control.

Claims

1. 1. A method for detecting multiple analytes in a sample, the method comprising performing a multiplex proximity-based detection assay, the assay comprising: (i) contacting the sample with a plurality of pairs of proximal probes, each pair including a first proximal probe and a second proximal probe, each proximal probe comprising: (a) an analyte-binding domain specific for the analyte; (b) a nucleic acid domain; both probes in each pair comprise analyte-binding domains specific for the same analyte and are capable of simultaneously binding to said analyte, and each probe pair is specific for a different analyte; the nucleic acid domain of each proximity probe comprises an ID sequence and at least a first hybridization sequence, the ID sequences of each proximity probe being different; In each proximity probe pair, the first proximity probe and the second proximity probe comprise paired hybridization sequences, and when the first proximity probe and the second proximity probe bind to the analyte, the paired hybridization sequences of the first proximity probe and the second proximity probe hybridize to each other or to a common splint oligonucleotide comprising a hybridization sequence complementary to each of the paired hybridization sequences of the first proximity probe and the second proximity probe; at least one pair of hybridization sequences is shared by at least two pairs of proximity probes; (ii) hybridizing the nucleic acid domains of the proximity probes to each other or to the splint oligonucleotide to form a continuous or discontinuous duplex comprising the hybridization sequence of a first proximity probe and the hybridization sequence of a second proximity probe, the duplex having at least one free 3' end; (iii) extending and / or ligating the duplex to produce extension and / or ligation products comprising the ID sequence of the first proximity probe and the ID sequence of the second proximity probe; (iv) amplifying the extension or ligation products; (v) detecting the extension products or ligation products, wherein the detection of the extension products or ligation products includes identifying the ID sequences therein, and determining the relative amount of each extension product or ligation product; (vi) determining which analytes are present in the sample, (a) extension and / or ligation products comprising a first ID sequence from a first proximity probe belonging to a first proximity probe pair and a second ID sequence from a second proximity probe belonging to a second proximity probe pair are considered background; (b) an extension product or ligation product comprising a first ID sequence and a second ID sequence from a proximity probe pair and present in an amount greater than the background indicates the presence of the analyte to which the proximity probe pair specifically binds in the sample.

2. The method of claim 1 , wherein the analyte is or comprises a protein.

3. The method of claim 1 or 2, wherein the analyte binding domain is an antibody or a fragment thereof.

4. Step (i) may further comprise filtering the sample with one or more background analytes that do not bind to the analyte. contacting the background probe with a background probe, the background probe comprising a nucleic acid domain comprising an ID sequence and a hybridization sequence shared with at least one proximity probe; The method of any one of claims 1 to 3, wherein extension products and / or ligation products generated as a result of interactions between background probes and proximity probes are detected in step (v) and considered as background in step (vi).

5. The method according to any one of claims 1 to 4, wherein the ID sequence is a barcode sequence.

6. The method of any one of claims 1 to 5, wherein at least one pair of hybridization sequences is unique to a single proximity probe pair.

7. The method of any one of claims 1 to 6, wherein no more than 10 proximity probe pairs share the same pair of hybridization sequences.

8. 8. The method of claim 7, wherein no more than five proximity probe pairs share the same pair of hybridization sequences.

9. The method of any one of claims 1 to 8, wherein at least 25% of the proximity probe pairs share their hybridization sequence pair with another proximity probe pair.

10. 10. The method of claim 9, wherein at least 50% of the proximity probe pairs share their hybridization sequence pair with another proximity probe pair.

11. 11. The method of claim 10, wherein at least 75% of the proximity probe pairs share their hybridization sequence pair with another proximity probe pair.

12. the proximity-based detection assay is a proximity extension assay, wherein the nucleic acid domains of each proximity-probe pair comprise complementary hybridization sequences that hybridize to each other to form a duplex; 12. A method according to any preceding claim, wherein the duplex is subjected to an extension reaction, the extension reaction comprising extending at least one free 3' end to produce an extension product comprising the ID sequence of the first proximity probe and the ID sequence of the second proximity probe.

13. 12. A method according to any preceding claim, wherein the proximity-based detection assay is a proximity ligation assay, wherein the nucleic acid domain of each proximity probe pair comprises paired hybridisation sequences for hybridising to a splint oligonucleotide to form a duplex, and wherein step (iii) comprises ligating, directly or indirectly, the nucleic acid domain of the first proximity probe to the nucleic acid domain of the second proximity probe to produce a ligation product comprising the ID sequence of the first proximity probe and the ID sequence of the second proximity probe.

14. 13. The method of claim 12, wherein in each proximity probe pair, at least one nucleic acid domain is partially double-stranded.

15. 15. The method of claim 14, wherein in each proximity probe pair, both nucleic acid domains are partially double-stranded.

16. The partially double-stranded nucleic acid domain comprises: (i) a first oligonucleotide conjugated to the analyte binding domain; (ii) a hybridization oligonucleotide comprising the first hybridization sequence, the ID sequence, and a second hybridization sequence, wherein the first hybridization sequence is located at the 3' end of the hybridization oligonucleotide; The method of claim 14 or 15, wherein the double-stranded portion of the nucleic acid domain comprises a duplex between the second hybridization sequence and the first oligonucleotide of the hybridization oligonucleotide, and the single-stranded portion of the nucleic acid domain comprises the first hybridization sequence of the hybridization oligonucleotide.

17. 17. The method of claim 16, wherein the hybridization oligonucleotide comprises, from the 5' end to the 3' end, the second hybridization sequence, the ID sequence, and the first hybridization sequence, and the ID sequence is located in the single-stranded portion of the nucleic acid domain.

18. 18. The method of claim 16 or 17, wherein at least one hybridization oligonucleotide is extended in step (iii) to generate the extension product.

19. 19. The method of any of claims 16 to 18, wherein in each proximity probe pair, both nucleic acid domains are partially double-stranded and one or both hybridization oligonucleotides are extended in step (iii) to produce the extension products.

20. The method according to any one of claims 1 to 19, wherein the nucleic acid domain is a DNA domain.

21. The method according to any one of claims 1 to 20, wherein in step (iv), the extension product or ligation product is amplified by PCR.

22. The method of any one of claims 1 to 21, wherein the extension product or ligation product is detected by nucleic acid sequencing.

23. 23. The method of claim 22, wherein one or more sequencing adapters are attached to the extension or ligation products in one or more amplification and / or ligation steps prior to sequencing.

24. In the step (iv), the extension product or ligation product is amplified in a first PCR reaction, and a first sequencing adapter is added to one end of the extension product or ligation product; 24. The method of claim 23, wherein the product of the first PCR reaction is amplified in a second PCR reaction and a second sequencing adapter is added to the other end of the extension or ligation product.

25. 25. The method of claim 24, wherein the first PCR reaction is performed with a nucleic acid polymerase that also has 3' to 5' exonuclease activity, and the second PCR reaction is performed with a nucleic acid polymerase that is deficient in 3' to 5' exonuclease activity.

26. 28. The method of any of claims 24 to 27, wherein a sample index sequence is attached to the extension or ligation products in an amplification or ligation step prior to sequencing, preferably wherein the sample index sequence is added to the extension or ligation products during PCR amplification in step (iv).

27. The method of any one of claims 22 to 26, wherein the nucleic acid sequencing is massively parallel DNA sequencing. Any of the methods described above.

28. The method according to any one of claims 1 to 27, wherein the sample is a plasma sample or a serum sample.

29. An article of manufacture comprising (i) a plurality of proximity probe pairs, and optionally (ii) a plurality of splint oligonucleotides, (i) among the plurality of proximal probe pairs, each proximal probe pair includes a first proximal probe and a second proximal probe, and each proximal probe (a) a protein-binding domain specific for a protein; (b) a nucleic acid domain; both probes in each pair comprise protein-binding domains specific for the same protein and are capable of simultaneously binding to said protein, and each probe pair is specific for a different protein; the nucleic acid domain of each proximity probe comprises an ID sequence and at least a first hybridization sequence, the ID sequences of each proximity probe being different, and in each proximity probe pair, the first proximity probe and the second proximity probe comprise paired hybridization sequences; (ii) each of said plurality of splint oligonucleotides comprises a hybridization sequence complementary to each of said paired hybridization sequences of a proximity probe pair; the hybridization sequences of each proximity probe pair are configured such that, when the first proximity probe and the second proximity probe bind to the protein, the paired hybridization sequences of the first proximity probe and the second proximity probe hybridize to each other or to a splint oligonucleotide; A product in which at least one pair of hybridization sequences is shared by at least two pairs of proximity probes.

30. 30. The article of manufacture of claim 29, wherein the protein binding domain is an antibody or a fragment thereof.

31. 31. The article of manufacture of claim 29 or 30, further comprising one or more background probes that do not bind to the analyte, said background probes comprising a nucleic acid domain that includes an ID sequence and a hybridization sequence shared with at least one proximity probe.

32. The product of any one of claims 29 to 31, wherein the ID sequence is a barcode sequence.

33. 33. An article according to any one of claims 29 to 32, wherein at least one pair of hybridisation sequences is unique to a single proximity probe pair.

34. 34. A product according to any one of claims 29 to 33, wherein no more than 10 proximity probe pairs share the same pair of hybridisation sequences.

35. 35. A product according to any one of claims 29 to 34, wherein at least 75% of the proximity probe pairs share their hybridisation sequence pairs with another proximity probe pair.

36. 36. A product according to any one of claims 29 to 35, wherein the nucleic acid domains of each proximity probe pair comprise complementary hybridisation sequences that are capable of hybridising to each other to form a duplex.

37. A product according to any one of claims 29 to 36, wherein the proximal probe pair is as defined in any one of claims 14 to 17 or claim 20.

Images